JP2024540579A5 - - Google Patents
Info
- Publication number
- JP2024540579A5 JP2024540579A5 JP2024529771A JP2024529771A JP2024540579A5 JP 2024540579 A5 JP2024540579 A5 JP 2024540579A5 JP 2024529771 A JP2024529771 A JP 2024529771A JP 2024529771 A JP2024529771 A JP 2024529771A JP 2024540579 A5 JP2024540579 A5 JP 2024540579A5
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- units
- pain
- clostridium neurotoxin
- neurotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2116774.7 | 2021-11-22 | ||
| GBGB2116774.7A GB202116774D0 (en) | 2021-11-22 | 2021-11-22 | Treatment of pain |
| GB2116795.2 | 2021-11-22 | ||
| GBGB2116795.2A GB202116795D0 (en) | 2021-11-22 | 2021-11-22 | Treatment of visceral pain |
| GB2206359.8 | 2022-04-29 | ||
| GBGB2206359.8A GB202206359D0 (en) | 2022-04-29 | 2022-04-29 | Treatment of pain |
| PCT/GB2022/052947 WO2023089338A1 (en) | 2021-11-22 | 2022-11-21 | Treatment of visceral pain |
| GBPCT/GB2022/052947 | 2022-11-21 | ||
| PCT/GB2022/052957 WO2023089343A1 (en) | 2021-11-22 | 2022-11-22 | Treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540579A JP2024540579A (ja) | 2024-10-31 |
| JP2024540579A5 true JP2024540579A5 (enExample) | 2025-12-01 |
Family
ID=84370182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529771A Pending JP2024540579A (ja) | 2021-11-22 | 2022-11-22 | 疼痛の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20260014237A1 (enExample) |
| EP (1) | EP4436594A1 (enExample) |
| JP (1) | JP2024540579A (enExample) |
| KR (1) | KR20240116485A (enExample) |
| AU (1) | AU2022392458A1 (enExample) |
| CA (1) | CA3234608A1 (enExample) |
| WO (1) | WO2023089343A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202307439D0 (en) * | 2023-05-18 | 2023-07-05 | Ipsen Biopharm Ltd | Treatment of a headache disorder with botylinum neurotoxin a |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| DK2154151T3 (da) | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
| WO2010120766A1 (en) | 2009-04-14 | 2010-10-21 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| EP2524963B1 (en) | 2011-05-19 | 2018-10-31 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| MX359480B (es) | 2012-05-30 | 2018-09-28 | President And Fellows Of Harvard College Star | Neurotoxina botulínica diseñada. |
| JP6156954B2 (ja) | 2012-11-21 | 2017-07-05 | イプセン バイオイノベーション リミテッド | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
| RU2746736C2 (ru) | 2015-03-26 | 2021-04-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Сконструированный ботулинический нейротоксин |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| SG11201810210UA (en) * | 2016-06-08 | 2018-12-28 | Childrens Medical Center | Engineered botulinum neurotoxins |
| EP3481852B1 (en) | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| BR112020006827A2 (pt) | 2018-01-29 | 2020-10-06 | Ipsen Biopharm Limited | neurotoxinas botulínicas clivando snare não neuronal |
| KR20220054371A (ko) * | 2019-08-30 | 2022-05-02 | 이온 바이오파마, 인크. | 두통 치료에 사용하기 위한 신경독소 조성물 |
| GB201914034D0 (en) * | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| TW202426039A (zh) * | 2020-03-16 | 2024-07-01 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
| GB202104294D0 (en) * | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| CN117396217A (zh) * | 2021-03-30 | 2024-01-12 | 益普生生物制药有限公司 | 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗 |
| JP2024513191A (ja) * | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
-
2022
- 2022-11-22 AU AU2022392458A patent/AU2022392458A1/en active Pending
- 2022-11-22 WO PCT/GB2022/052957 patent/WO2023089343A1/en not_active Ceased
- 2022-11-22 CA CA3234608A patent/CA3234608A1/en active Pending
- 2022-11-22 EP EP22817312.6A patent/EP4436594A1/en active Pending
- 2022-11-22 JP JP2024529771A patent/JP2024540579A/ja active Pending
- 2022-11-22 US US18/711,074 patent/US20260014237A1/en active Pending
- 2022-11-22 KR KR1020247020412A patent/KR20240116485A/ko active Pending
-
2025
- 2025-09-26 US US19/342,035 patent/US20260021170A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2332406C (en) | Treatment of neuromuscular disorders and conditions with different botulinum serotype | |
| EP0702559B1 (en) | Multiple botulinum toxins for treating neuromuscular disorders and conditions | |
| JP2024534541A5 (enExample) | ||
| KR20140142377A (ko) | 보툴리눔 독소의 신경독성 성분의 고 빈도 사용 | |
| EP2214696A1 (en) | Methods of treating chronic neurogenic inflammation using modified clostridial toxins | |
| US20100303757A1 (en) | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases | |
| Marciniec et al. | Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: what is currently known? | |
| US9278133B2 (en) | Highly purified type A botulinum toxin preparation from infant botulism pathogen | |
| Thakker et al. | Pharmacology and clinical applications of botulinum toxins A and B | |
| JP7524058B2 (ja) | ボツリヌス神経毒素ａサブタイプ６および薬理学的使用方法 | |
| JP2011157331A (ja) | 高用量投与が可能なボツリヌス毒素製剤 | |
| Değirmenci | A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience | |
| RU2025130480A (ru) | Лечение головной боли ботулиническим нейротоксином А | |
| US20240207303A1 (en) | mNA-based Delivery of Botulinum Toxin | |
| Works et al. | BOTULINUM TOXIN TYPE A | |
| Alter et al. | Botulinum Neurotoxins for the Treatment of Headache | |
| Vistabel | B Class | |
| HK1061648B (en) | Treatment of neuromuscular disorders and conditions with different botulinum serotype | |
| AU5356900A (en) | Treatment of neuromuscular disorders and conditions with different botulinum serotype |